Physiomics has secured new contracts worth more than £205,000, bringing the total value of work won over the past four months to more than £750,000.
The AIM-listed company, which provides mathematical modelling, data science and biostatistics services to support drug development and personalised medicine, said the latest awards spanned its various service lines and reflected strengthening demand for its expertise.
It added that it was seeing growing interest from international research and clinical collaborations exploring new approaches to cancer treatment, and was pursuing further opportunities.
The company said the pace of recent contract wins reflected the early impact of a shift towards a more commercially focused organisation, following the recent promotion of Jesse Thissen to chief operating officer.
Mike Whitlow, Executive Director of Physiomics, said: “Securing further contracted work represents another important step forward for Physiomics. In a little over four months, the Company has announced contract awards with a total value of more than £750,000, which is approximately 95% of the revenue reported for the whole of the financial year 2024-2025.
“While contract value is recognised as revenue over the relevant project delivery periods, the Board believes this level of new business provides a strong indication of the commercial progress being made by the Company.
“This progress reflects a substantial collective effort across the business. The Board has focused on providing clear oversight, strengthening commercial accountability and ensuring that the Company is positioned to pursue and deliver a broader range of opportunities.
“We are particularly encouraged that interest in Physiomics extends beyond conventional commercial engagements. The Company is increasingly being recognised as a potential contributor to ambitious international research and clinical collaborations in areas where predictive modelling, data science and personalised medicine are becoming increasingly important.”